Clinical Research Directory

Inclusion Criteria: * Patient must be willing and capable of giving written Informed Consent and must be able to adhere to dosing and visit schedules as well as meet all study requirements * Patient is diagnosed with advanced solid tumor or hematological malignancy. * Patient is at least 18 years of age and has a life expectancy of at least 6 months. * Patient has normal or abnormal hepatic function as defined by normal, mild (Child-Pugh A), moderate (Child-Pugh B ), or severe (Child-Pugh C) liver impairment * Patient has adequate hematologic and renal function as defined by: Absolute neutrophil count (ANC) ≥1000/μL Platelet count ≥100,000/μL Creatinine ≤ 1.5 mg/dL or calculated creatinine clearance ≥50 mL/min * Patient has an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2. * Patient is willing to practice 2 forms of contraception, one of which must be a barrier method, from study entry until at least 30 days after the last dose of pralatrexate * Females of childbearing potential must have a negative pregnancy test within 30 days prior to enrollment. Females who are postmenopausal for at least 1 year (defined as more than 12 months since last menses) or who are surgically sterilized do not require this test. Exclusion Criteria: * Patient has had previous exposure to pralatrexate * Patient has used any investigational drugs, biologics, or devices within 30 days prior to study treatment or plans to use any of these during the course of the study. * Patient has an active, uncontrolled infection, underlying medical condition, or other serious illness that would impair the patient's ability to receive the protocol-defined treatment. * Patient has known or suspected intolerance or hypersensitivity to the investigational product or any related compound. * Patient has congestive heart failure at Class III/IV according to the New York Heart Association (NYHA) Functional Classification * Patient has had major surgery within 30 days prior to enrollment. * Patient with central nervous system (CNS) metastases * Patient is pregnant or breast-feeding.